Home > Journals > Minerva Pneumologica > Past Issues > Minerva Pneumologica 2013 June-September;52(2-3) > Minerva Pneumologica 2013 June-September;52(2-3):61-75

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

  TREATING RESPIRATORY DISEASE 

Minerva Pneumologica 2013 June-September;52(2-3):61-75

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

Ventilator associated pneumonias - What’s new after ATS/IDSA Guidelines 2005?

Lee C. P., Lim A. Y. H., Abisheganaden J.

Department of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore


PDF


Ventilator associated pneumonia (VAP) causes significant morbidity and mortality worldwide. Incidence rate of VAP ranges from as low as zero in developed countries to as high as 40 per 1000 mechanical ventilation days in developing countries. Comparisons of VAP rates remain a challenge as VAP case definitions differ amongst countries. The top 6 pathogens including, Staphylococcus aureus, Pseudomonas aeruginosa, Enterobacter species, Klebsiella species, Serratia species and Acinetobacter species, accounted for the large majority of cases of VAP. Community acquired organisms and antibiotic-sensitive enteric gram-negative bacilli were common isolates in early VAP whereas methicillin-resistant Staphylococcus aureus and multi-drug resistant (MDR) gram negative bacilli predominate in late VAP. There has been an increased awareness in the pathogenesis of VAP that has renewed interest in the prevention of VAP. Diagnosis of VAP is guided by clinical criteria and microbiological data from invasive and non-invasive methods of respiratory specimen collection. Combination therapy is the mainstay of antimicrobial treatment in patients with risk factors for MDR organisms. Major changes since the publication of the 2005 American Thoracic Society/Infectious Disease Society of America guidelines on VAP are discussed in this review.

top of page